文献速递肿瘤 PET/CT

[18F]ICMT-11 PET 检测乳腺癌与肺癌化疗诱导的 caspase 3/7 激活的临床转化

Clinical translation of [18F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-09-27

本研究将 caspase-3/7 特异性示踪剂 [18F]ICMT-11 PET 用于接受一线化疗的乳腺癌和肺癌患者,检测化疗诱导的 caspase-3/7 激活。乳腺癌肿瘤基线 SUVmax 低且治疗后无变化,M30/M60 检测显示治疗主要非凋亡性;肺癌中 PET 变化与细胞死亡一致且无明显灌注变化。研究认为 [18F]ICMT-11 PET 是有前景的无创 caspase3/7 激活成像候选方法,但评估早期治疗反应存在困难。

要点

  • 乳腺癌肿瘤 [18F]ICMT-11 基线 SUVmax 低且治疗后无变化。
  • M30/M60 检测显示治疗主要非凋亡性,caspase-3 阳性率约 1%。
  • 肿瘤缓解可在无显著化疗诱导 caspase-3/7 激活时发生。

核心结论

  • 本研究提示 [18F]ICMT-11 PET 是有前景的无创 caspase3/7 激活成像候选方法,并凸显评估早期治疗反应所遇困难。
  • 作者总结认为,乳腺癌和肺癌患者整个肿瘤病灶无创测得化疗诱导的 caspase-3/7 激活不占主导时,肿瘤缓解仍可发生。

研究设计与样本

  • 本研究为 [18F]ICMT-11 PET 的临床转化研究,纳入接受一线治疗的乳腺癌和肺癌患者。
  • 乳腺癌患者 15 例中 14 例对一线化疗有反应(完全或部分缓解),1 例疾病稳定。

主要发现

  • 乳腺癌肿瘤 [18F]ICMT-11 的 SUVmax 在基线低且治疗后无变化。
  • M30/M60 细胞角蛋白-18 裂解产物检测显示治疗主要非凋亡性。
  • 乳腺癌组织学 caspase-3 染色虽增加,但治疗后 caspase-3 阳性值仅约 1%。
  • 15 例乳腺癌患者中 4 例在肿瘤数据体素分析中显示高 [18F]ICMT-11 强度区域增加(分类为 PADS),反应不限于该表型患者。
  • 肺癌患者多参数 [18F]ICMT-11 PET 与 MRI(弥散加权和动态增强 MRI)显示 PET 变化与细胞死亡一致,无明显灌注变化。

临床怎么用

  • 作者认为 [18F]ICMT-11 PET 是有前景的无创 caspase3/7 激活成像候选方法。
  • 作者总结认为肿瘤缓解可在无主导性化疗诱导的 caspase-3/7 激活时发生。

局限性

  • 治疗后 caspase-3 阳性值仅约 1%,这一低水平可能限制了 [18F]ICMT-11 PET 的敏感检测。
  • 本研究凸显了评估早期治疗反应所遇困难。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Effective anticancer therapy is thought to involve induction of tumour cell death through apoptosis and/or necrosis. [18F]ICMT-11, an isatin sulfonamide caspase-3/7-specific radiotracer, has been developed for PET imaging and shown to have favourable dosimetry, safety, and biodistribution. We report the translation of [18F]ICMT-11 PET to measure chemotherapy-induced caspase-3/7 activation in breast and lung cancer patients receiving first-line therapy. RESULTS: Breast tumour SUVmax of [18F]ICMT-11 was low at baseline and unchanged following therapy. Measurement of M30/M60 cytokeratin-18 cleavage products showed that therapy was predominantly not apoptosis in nature. While increases in caspase-3 staining on breast histology were seen, post-treatment caspase-3 positivity values were only approximately 1%; this low level of caspase-3 could have limited sensitive detection by [18F]ICMT-11-PET. Fourteen out of 15 breast cancer patients responded to first-line chemotherapy (complete or partial response); one patient had stable disease. Four patients showed increases in regions of high tumour [18F]ICMT-11 intensity on voxel-wise analysis of tumour data (classed as PADS); response was not exclusive to patients with this phenotype. In patients with lung cancer, multi-parametric [18F]ICMT-11 PET and MRI (diffusion-weighted- and dynamic contrast enhanced-MRI) showed that PET changes were concordant with cell death in the absence of significant perfusion changes. CONCLUSION: This study highlights the potential use of [18F]ICMT-11 PET as a promising candidate for non-invasive imaging of caspase3/7 activation, and the difficulties encountered in assessing early-treatment responses. We summarize that tumour response could occur in the absence of predominant chemotherapy-induced caspase-3/7 activation measured non-invasively across entire tumour lesions in patients with breast and lung cancer.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Dubash SR, Merchant S, Heinzmann K, et al. Clinical translation of [18F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer. Eur J Nucl Med Mol Imaging. 2018. PMID: 30259091. doi:10.1007/s00259-018-4098-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。